The days are getting shorter as we "fall back” into standard time and it may be affecting your mood. While we settle into our ...

Efforts have been made in recent years to clarify the value of exercise as an adjunctive or independent treatment for major ...

Seasonal Affective Disorder (SAD) affects millions of Americans, and cases usually start to rise in late fall or early winter ...

The following is a summary of “Voice of depression: speech features as biomarkers for major depressive disorder,” published ...

The Horizon 3.0 TMS Therapy System is a computerized, noninvasive medical device that directs electrical currents at different regions of the cerebral cortex.

People suffering from major depressive disorder (MDD) and treatment-resistant depression (TRD) often face challenging ...

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...

Cybin (Cboe CA:CYBN) has begun its Phase 3 pivotal program, PARADIGM, to evaluate the efficacy and safety of CYB003 as an ...

One study suggests these drugs could increase depression risk in heart attack survivors who retained normal heart pumping ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good morning, and welcome to the Axsome Therapeutics Third ...

Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment ...

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revoluti ...